Pittsburgh to Build New Cancer Center
PITTSBURGH-To accommodate the growth of the University of Pittsburgh Cancer Institute’s (UPCI’s) treatment and research activities, the UPMC Health System will build a 295,000 square-foot integrated facility on the UPMC Shadyside campus. This $104 million building will serve as the hub for UPCI’s clinical programs and scientific investigations.
PITTSBURGHTo accommodate the growth of the University of Pittsburgh Cancer Institutes (UPCIs) treatment and research activities, the UPMC Health System will build a 295,000 square-foot integrated facility on the UPMC Shadyside campus. This $104 million building will serve as the hub for UPCIs clinical programs and scientific investigations.
UPCI includes more than 600 scientists and health care professionals in more than 30 disciplines. It is the only NCI-designated comprehensive cancer center in western Pennsylvania.
This new building symbolizes the commitment of the UPMC Health System to combat this disease, which touches every family and which is the second-leading cause of death in the United States, said Jeffrey Romoff, president of the UPMC.
The new building will more than double current research space and allow for the recruitment of 250 new scientists and clinicians. Groundbreaking on the building will begin in the spring of this year.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
